[1. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016;37(5):467-520. doi:10.1210/er.2015-1104.10.1210/er.2015-1104]Open DOISearch in Google Scholar
[2. Melo AS, Dias SV, Cavalli RC, Cardoso VC, Bettiol H, Barbieri MA, et al. Pathogenesis of polycystic ovary syndrome: multifactorial assessment from the foetal stage to menopause. Reproduction. 2015;150(1):R11-24.10.1530/REP-14-0499]Search in Google Scholar
[3. Zueff LFN, Martins WP, Vieira CS, Ferriani RA. Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound Obstet Gynecol. 2012;39(3):341-7.10.1002/uog.10084]Search in Google Scholar
[4. Sir-Petermann T, Angel B, Maliqueo M, Carvajal F, Santos JL, Perez-Bravo F. Prevalence of type II diabetes mellitus and insulin resistance in parents of women with polycystic ovary syndrome. Diabetologia. 2002;45:959-64.10.1007/s00125-002-0836-3]Search in Google Scholar
[5. Kiddy DS, Sharp PS, White DM, Scanlon MF, Mason HD, Bray CS, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol (Oxf). 1990;32(2):213-20.10.1111/j.1365-2265.1990.tb00857.x]Search in Google Scholar
[6. Legro RS, Strauss JF. Molecular progress in infertility: polycystic ovary syndrome”. Fertility and Sterility. 2002;78 (3):569-76.10.1016/S0015-0282(02)03275-2]Search in Google Scholar
[7. Crosignani PG, Nicolosi AE. Polycystic ovarian disease: heritability and heterogeneity. Hum Reprod. 2001;7(1):3-7.10.1093/humupd/7.1.3]Search in Google Scholar
[8. Sampson M, Kong C, Patel A, Unwin R & Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol. 1996;45(5):623-9.10.1046/j.1365-2265.1996.00863.x]Search in Google Scholar
[9. Lee YH, Song GG. Plasminogen activator inhibitor-1 4G/5G and the MTHFR 677C/T polymorphisms and susceptibility to polycystic ovary syndrome: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2014;175:8-14.10.1016/j.ejogrb.2013.12.030]Search in Google Scholar
[10. Orio F Jr, Palomba S, Cascella T, Tauchmanova L, Nardo LG, Labella D, et al. Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? Reprod Biomed Online. 2004;9(5):505-10.10.1016/S1472-6483(10)61634-3]Search in Google Scholar
[11. Glueck CJ, Wanga P, Bornovali S, Goldenberg N, Sieve L. Polycystic ovary syndrome, the G1691A factor V Leiden mutation, and plasminogen activator inhibitor activity: associations with recurrent pregnancy loss. Metabolism. 2003;52(12):1627-32.10.1016/j.metabol.2003.06.00114669168]Search in Google Scholar
[12. Tsanadis G, Vartholomatos G, Korkontzelos I, Avgoustatos F, Kakosimos G, Sotiriadis A, et al. Polycystic ovarian syndrome and thrombophilia. Hum Reprod. 2002;17(2):314-9.10.1093/humrep/17.2.31411821270]Search in Google Scholar
[13. T. Kazerooni, F. Ghaffarpasand, N. Asadi, Z. Dehkhoda,M. Dehghankhalili, Y. Kazerooni. Correlation between thrombophilia and recurrent pregnancy loss in patients with polycystic ovary syndrome: A comparative study. J Chin Med Assoc. 2013;76(5):282-8.10.1016/j.jcma.2013.01.00923683262]Search in Google Scholar
[14. Moini A, Tadayon S, Tehranian A, Yeganeh LM, Akhoond MR, Yazdi RS. Association of thrombophilia and polycystic ovarian syndrome in women with history of recurrent pregnancy loss. Gynecol Endocrinol. 2012;28(8):590-593.10.3109/09513590.2011.65075422452370]Search in Google Scholar
[15. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-7.10.1093/humrep/deh09814688154]Search in Google Scholar
[16. Komsa-Penkova R, Kovacheva-Kotseva K, Angelova S, Savov A, Semionova M. [Selected methods of DNA analysis and clinical applications]. Pleven: Medical University - Pleven; 2004. Bulgarian]Search in Google Scholar
[17. Lash GE, Naruse K, Innes BA, Robson SC, Searle RF, Bulmer JN. Secretion of angiogenic growth factors by villous cytotrophoblast and extravillous trophoblast in early human pregnancy. Placenta. 2010;31(6):545-8.10.1016/j.placenta.2010.02.02020338637]Search in Google Scholar
[18. Schatz F, Guzeloglu-Kayisli O, Arlier S1, Kayisli UA, Lockwood CJ. The role of decidual cells in uterine hemostasis, menstruation, inflammation, adverse pregnancy outcomes and abnormal uterine bleeding. Hum Reprod . 2016;22(4):497-515.10.1093/humupd/dmw004491774226912000]Search in Google Scholar
[19. Ivanov P, Komsa-Penkova R, Kovacheva K, Konova E, Simeonova M. Influence of factor V LEIDEN carrier on the development of reproductive disorders in different periods of pregnancy. Medical review. 2008;1:68-71.]Search in Google Scholar
[20. Ivanov P, Konova E, Gecheva S, Cviatkovska C, Izmajlov A, Komsa-Penkova R. et al. Factor V Leiden in assisted reproductive technology. Obstetrics and Gynecology.2013; 6:11-14.]Search in Google Scholar
[21. Atiomo WU, Condon J, Adekanmi O, Friend J, Wilkin TJ, Prentice AG. Are women with polycystic ovary syndrome resistant to activated protein C? Fertil Steril. 2000;74:1229-1232.10.1016/S0015-0282(00)01614-9]Search in Google Scholar